Regarding the parameters related to kidney function, patients with Obesity/T2DM showed lower eGFR compared to their counterparts without T2DM ( p < 0.001) with a significant trend across the groups ( p = 0.035) (Fig. 1 ).
← all phrases
“a significant trend”
Sighted at
p=0.09
In the literature
There was a significant trend with average hours of night work per week ( P = 0.035), but no significantly raised risks for hours worked per night, nights worked per week, average hours worked per week, cumulative years of employment, cumulative hours, time since cessation, type of occupation, age starting night shift work, or age starting in relation to first pregnancy.
DRA in 1 cohort revealed a significant trend between sTG and SAH risk only in the linear model (Model 1, P = 0.035), with a decreasing risk of 54.0% (95% CI 5.5%~77.6%, P = 0.035) per mmol/L sTG increase (Fig. 5 D; Table 2 ).
Patients with lepromatous leprosy had a non-significant trend (p = 0.16) of decreasing CCL17 levels ( Figure 5A ) and a significant trend (p = 0.036) of increasing CCL18 ( Figure 5B ) levels in the serum.
Trend for FH Genetic Testing Interestingly, we found a significant trend ( p = 0.036) when we compared the rate of genetic testing before and after the insurance coverage in Japan ( Supplemental Table 3 ) . 3.7.
A significant trend between the uni, oligo, and multi groups for location of TL PD (Fig. 5 B; p = 0.036) was detected, with patients with progression of only one TL having a longer OS.
When the frequency of abnormal expression of individual proteins was correlated with tumour grade using the Mantel-extension χ 2 test for trends, there was a significant trend to an increase in abnormal BRCA1 expression with higher grade ( P= 0.036) ( Figure 3 ).
Although the percentage of patients who died or experienced worsening HF at 14 days was lower and the percentage of patients with myocardial ischaemia was higher in the levosimendan group, the differences did not reach statistical significance.[ 41 ] Overall, the percentage of patients meeting the primary composite endpoint criteria at 14 days was lower, albeit not significantly, with levosimendan (21.2% versus 26.2%).[ 41 ] At 6 months, the non-significant trends for death and worsening HF were supplemented by a significant trend for a lower incidence of MI in the levosimendan group between 14 days and 6 months (3.8% versus 13.8%; HR 0.261; p=0.036).[ 41 ] As a result, there was a significant treatment effect of levosimendan on the composite primary endpoint (43.7% versus 62.5%; HR 0.636; 95% CI [0.413–0.981]; p=0.041; Figu
A significant trend was observed (P = 0.036).
When the severity of IVH was assessed in relation to the presence of MVM, there was a significant trend (Cochran-Armitage p -value = 0.0362), and the Fisher’s exact approached significance ( p = 0.0743).
A significant trend with increasing mother's age (p = 0.037) and father's age (p = 0.005) was found.
Conversely, there was a significant trend toward lower ECM biomass production under eCO 2 compared to aCO 2 in winter ( P = 0.037).
A significant trend was observed between higher 5‐SENSE scores and better seizure outcomes ( p = 0.037; Table S3 ).
Lanes 1 and 2 Patient 1, Normal tissue and cancer tissue; Lanes 3 and 4 Patient 2, Normal tissue and cancer tissue; Lanes 5 and 6 Patient 3, Normal (Void) and cancer tissue; Lanes 7 and 8 Patient 4, Normal tissue and cancer tissue; Lanes 9 and 10 Patient 5, Normal tissue and cancer tissue; Lanes 11 and 12 Patient 6, Normal tissue and cancer tissue; Lane 13, Water negative control; Lane 14, SW948 positive control. 192 RCA Macadam et al British Journal of Cancer (2000) 83(2), 188-195 (c) 2000 Cancer Research Campaign examined, there was a significant trend indicating a diminished 5-year survival in node-negative patients whose tumours co-expressed REG and PAP (Figure 5) (Chi-squared = 8.46, P = 0.037).
However, women with BMI ≥ 25.0 kg/m 2 demonstrated the strongest associations, with the second lowest MAR quartile showing the highest risk (OR = 4.20, 95% CI: 1.30–13.50), followed by the lowest quartile (OR = 3.17) and third quartile (OR = 2.64), with a significant trend ( p = 0.037).
For both PFS and OS, there was a significant trend of bevacizumab being more effective when given early (ie, as first-line rather than as second- or later-line treatment; PFS P =0.037 and OS P <0.001).
The ORs consistently decreased from T1 to T3 with increasing PHDI, demonstrating a significant trend ( P = .037).
A significant trend was observed with increasing iron levels from no IPA to probable IPA (Jonckheere-Terpstra Test, p = 0.038).
Although the relationships between vigour and inertia, boredom or impulsivity were always positive, only a significant trend was found between boredom proneness and vigour (p = 0.038).
We observed a significant trend of decreased tumor growth with this treatment (P=0.038) ( Fig. 5 ).
Time of admission also showed a significant trend (p=0.038), with lesser patients presenting over the night shift as the months progressed in the COVID era.
A positive response to CS was observed in 15 of 17 group 1 volunteers (83%), compared with just 9 of 16 volunteers in group 2 (56%), with a significantly higher frequency of IFN-γ–producing CD4 + T cells in group 1 (Figure 6 C ). Ex vivo IFN-γ ELISPOT analysis revealed a trend toward higher responses to CS peptides in group 1 as compared to group 2 ( P = .0517, by the Mann–Whitney test on combined groups); when assessed by peptide pool, a significant trend toward higher responses was observed in pool 1 ( P = .0380, by the Mann–Whitney test).
Condition-by-order-by-sex comparisons revealed significant interaction effects for ratings of ease of falling asleep (F (1, 17.44) = 5.15, p = 0.036) ( Table 4 ), with post hoc analysis reporting a significant trend for females in the CON condition who completed the CON condition first (mean difference = −1.202, SE = 0.348, t (38.757) = −3.449, p = 0.038).
There was a significant trend for the eukaryotes ( F = 2.723, p = 0.039, Fig.
There was a significant trend in the dose–response relationship between rivaroxaban and major bleeding ( P =0.039).